Cargando…

myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology

myCOPD is a digital tool designed for people to manage their chronic obstructive pulmonary disease (COPD). It requires a device with an internet connection and incorporates tools for education, self-management, symptom tracking and pulmonary rehabilitation (PR). myCOPD was selected for medical techn...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Heather, Chappell, Mary, Wang, Yingying, Phalguni, Angaja, Wake, Stephanie, Arber, Mick, Shore, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403412/
https://www.ncbi.nlm.nih.gov/pubmed/37246188
http://dx.doi.org/10.1007/s40258-023-00811-x
_version_ 1785085062110248960
author Davies, Heather
Chappell, Mary
Wang, Yingying
Phalguni, Angaja
Wake, Stephanie
Arber, Mick
Shore, Judith
author_facet Davies, Heather
Chappell, Mary
Wang, Yingying
Phalguni, Angaja
Wake, Stephanie
Arber, Mick
Shore, Judith
author_sort Davies, Heather
collection PubMed
description myCOPD is a digital tool designed for people to manage their chronic obstructive pulmonary disease (COPD). It requires a device with an internet connection and incorporates tools for education, self-management, symptom tracking and pulmonary rehabilitation (PR). myCOPD was selected for medical technologies guidance by the UK National Institute for Health and Care Excellence (NICE) in 2020. The External Assessment Group (EAG) critiqued the company’s submission. The evidence comprised four clinical studies (three randomised controlled trials [RCTs] and one observational study) and real-world evidence from 22 documents. The RCTs had small sample sizes, limiting the power to detect statistically significant differences and to match patient characteristics across arms. The company produced two de novo models for two subgroups of people with COPD; people discharged from hospital with acute exacerbation of COPD (AECOPD) and people referred for PR. After the EAG updated input parameters and adjusted the model structures, cost savings of £86,297 per clinical commissioning group (CCG) compared with standard care were estimated for the AECOPD population, with myCOPD predicted to be cost saving in 74% of iterations. Cost savings of £22,779 per CCG were estimated for the PR population (with the assumption that the CCG had an existing myCOPD licence), with myCOPD predicted to be cost saving in 86% of the iterations. The Medical Technologies Advisory Committee concluded that although myCOPD has the potential to help manage COPD in adults, further evidence is required to address uncertainties in the current evidence base. NICE published this as Medical Technology Guidance 68 (National Institute for Health and Care Excellence (NICE). myCOPD for managing chronic obstructive pulmonary disease. 2022. Available at: https://www.nice.org.uk/guidance/mtg68/). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-023-00811-x.
format Online
Article
Text
id pubmed-10403412
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-104034122023-08-06 myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology Davies, Heather Chappell, Mary Wang, Yingying Phalguni, Angaja Wake, Stephanie Arber, Mick Shore, Judith Appl Health Econ Health Policy Review Article myCOPD is a digital tool designed for people to manage their chronic obstructive pulmonary disease (COPD). It requires a device with an internet connection and incorporates tools for education, self-management, symptom tracking and pulmonary rehabilitation (PR). myCOPD was selected for medical technologies guidance by the UK National Institute for Health and Care Excellence (NICE) in 2020. The External Assessment Group (EAG) critiqued the company’s submission. The evidence comprised four clinical studies (three randomised controlled trials [RCTs] and one observational study) and real-world evidence from 22 documents. The RCTs had small sample sizes, limiting the power to detect statistically significant differences and to match patient characteristics across arms. The company produced two de novo models for two subgroups of people with COPD; people discharged from hospital with acute exacerbation of COPD (AECOPD) and people referred for PR. After the EAG updated input parameters and adjusted the model structures, cost savings of £86,297 per clinical commissioning group (CCG) compared with standard care were estimated for the AECOPD population, with myCOPD predicted to be cost saving in 74% of iterations. Cost savings of £22,779 per CCG were estimated for the PR population (with the assumption that the CCG had an existing myCOPD licence), with myCOPD predicted to be cost saving in 86% of the iterations. The Medical Technologies Advisory Committee concluded that although myCOPD has the potential to help manage COPD in adults, further evidence is required to address uncertainties in the current evidence base. NICE published this as Medical Technology Guidance 68 (National Institute for Health and Care Excellence (NICE). myCOPD for managing chronic obstructive pulmonary disease. 2022. Available at: https://www.nice.org.uk/guidance/mtg68/). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-023-00811-x. Springer International Publishing 2023-05-28 2023 /pmc/articles/PMC10403412/ /pubmed/37246188 http://dx.doi.org/10.1007/s40258-023-00811-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review Article
Davies, Heather
Chappell, Mary
Wang, Yingying
Phalguni, Angaja
Wake, Stephanie
Arber, Mick
Shore, Judith
myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology
title myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology
title_full myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology
title_fullStr myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology
title_full_unstemmed myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology
title_short myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology
title_sort mycopd app for managing chronic obstructive pulmonary disease: a nice medical technology guidance for a digital health technology
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403412/
https://www.ncbi.nlm.nih.gov/pubmed/37246188
http://dx.doi.org/10.1007/s40258-023-00811-x
work_keys_str_mv AT daviesheather mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology
AT chappellmary mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology
AT wangyingying mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology
AT phalguniangaja mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology
AT wakestephanie mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology
AT arbermick mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology
AT shorejudith mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology